Pilonidal Sinus Disease with abscess. Pilonidal sinus with abscess
Conditions
Interventions
Intervention 1: In intervention group,the obtained PRP was additionally injected into the depth (13mm) of the wound. It was also applied to center of each circle (0.1cc) and wound site (1 cm in diamet
Treatment - Drugs
In intervention group,the obtained PRP was additionally injected into the depth (13mm) of the wound. It was also applied to center of each circle (0.1cc) and wound site (1 cm in diameter) through inje
Classical dressing (sterile absorbent cotton gauze) was applied for the control group. Washing the wound with normal saline (0.9%) twice a day was ordered. Wound debridement was also done in order to
Sponsors
Vice chancellor for research,Tehran University of Medical Sciences.
Eligibility
Sex/Gender
All
Age
18 Years to 47 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Any patient diagnosed with pilonidal sinus disease with a scheduled surgery. Exclusion criteria: lower platelet count of <103/µL; hemoglobin <10 mg/dl; anti-proliferative therapies such as chemotherapy and also radiation in past 3 months; anti-inflammation medications in past 2 weeks; growth factor therapies in last 2 weeks, history of diabetes, history of mal-absorption (celiac disease); any contra-indication in peripheral venues access ; not willing to participate in the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Wound healing time. Timepoint: Weekly up to full healing. Method of measurement: Wound volume measurement by filling the wound with saline. The volume dispensed from the syringe equals the wound volume.;Quality of life. Timepoint: Weekly after start treatment up to average 8 weeks. Method of measurement: Quality of life questionnaire SF12 and 26. | — |
Secondary
| Measure | Time frame |
|---|---|
| Angiogenesis. Timepoint: In PRP group: between 4-6 weeks In control group: between 8-10 weeks. Method of measurement: Immuno Histochemistery (IHC) on biopsy sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKamran Alimoghadam
Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sci
Outcome results
None listed